Triple-negative breast cancer: promising prognostic biomarkers currently in development
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Triple-negative breast cancer: promising prognostic biomarkers currently in development
Authors
Keywords
-
Journal
Expert Review of Anticancer Therapy
Volume -, Issue -, Pages -
Publisher
Informa UK Limited
Online
2020-11-17
DOI
10.1080/14737140.2021.1840984
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Application of circulating tumor DNA in breast cancer
- (2020) Yuan Zhao et al. Breast Journal
- Using next‐generation sequencing to redefine BRCAness in triple‐negative breast cancer
- (2020) Po‐Han Lin et al. CANCER SCIENCE
- Pembrolizumab for Early Triple-Negative Breast Cancer
- (2020) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Metastatic breast cancer patient perceptions of somatic tumor genomic testing
- (2020) Elizabeth J. Adams et al. BMC CANCER
- Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
- (2020) Heather A. Parsons et al. CLINICAL CANCER RESEARCH
- HER2-Low Breast Cancer: Pathological and Clinical Landscape
- (2020) Paolo Tarantino et al. JOURNAL OF CLINICAL ONCOLOGY
- Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
- (2019) Aditya Bardia et al. NEW ENGLAND JOURNAL OF MEDICINE
- A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer – clinical results and biomarker analysis of GeparNuevo study
- (2019) S Loibl et al. ANNALS OF ONCOLOGY
- A Single-Cell Atlas of the Tumor and Immune Ecosystem of Human Breast Cancer
- (2019) Johanna Wagner et al. CELL
- AL101 mediated tumor inhibition in notch-altered TNBC PDX models.
- (2019) Esther Channah Broner et al. JOURNAL OF CLINICAL ONCOLOGY
- Genomic characterization of metastatic breast cancers
- (2019) François Bertucci et al. NATURE
- Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer
- (2019) Fabrice André et al. NEW ENGLAND JOURNAL OF MEDICINE
- PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer
- (2019) Constantia Pantelidou et al. Cancer Discovery
- Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019
- (2019) H J Burstein et al. ANNALS OF ONCOLOGY
- Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial
- (2019) Peter Schmid et al. JOURNAL OF CLINICAL ONCOLOGY
- NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+
- (2019) Louis Fehrenbacher et al. JOURNAL OF CLINICAL ONCOLOGY
- Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
- (2019) Robert C Doebele et al. LANCET ONCOLOGY
- PI3K Inhibitors in Breast Cancer Therapy
- (2019) Haley Ellis et al. Current Oncology Reports
- Targeting FGFR pathway in breast cancer
- (2018) J. Perez-Garcia et al. BREAST
- Mutant p53 in breast cancer: potential as a therapeutic target and biomarker
- (2018) Michael J. Duffy et al. BREAST CANCER RESEARCH AND TREATMENT
- Implementing Liquid Biopsies in Clinical Trials
- (2018) Maryam B. Lustberg et al. CANCER JOURNAL
- Abstract P2-09-15:NTRKfusions in breast cancer: Clinical, pathologic and genomic findings
- (2018) JS Ross et al. CANCER RESEARCH
- Epidermal growth factor receptor overexpression and outcomes in early breast cancer: A systematic review and a meta-analysis
- (2018) Galileo A. Gonzalez-Conchas et al. CANCER TREATMENT REVIEWS
- Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer
- (2018) Daniel G. Stover et al. JOURNAL OF CLINICAL ONCOLOGY
- Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer
- (2018) Tiffany A. Traina et al. JOURNAL OF CLINICAL ONCOLOGY
- Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study
- (2018) Ellen R Copson et al. LANCET ONCOLOGY
- Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
- (2018) Carsten Denkert et al. LANCET ONCOLOGY
- Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
- (2018) Sibylle Loibl et al. LANCET ONCOLOGY
- Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
- (2018) Andrew Tutt et al. NATURE MEDICINE
- Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy
- (2018) Angela Santonja et al. Oncotarget
- Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer
- (2018) Naoko Matsuda et al. JAMA Oncology
- Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial
- (2018) Ines Stevic et al. BMC Medicine
- Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node–Positive and High-Risk Lymph Node–Negative Breast Cancer (E5103)
- (2018) Kathy D. Miller et al. JOURNAL OF CLINICAL ONCOLOGY
- OUP accepted manuscript
- (2018) JNCI-Journal of the National Cancer Institute
- Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
- (2018) Jennifer K. Litton et al. NEW ENGLAND JOURNAL OF MEDICINE
- MicroRNA in diagnosis and therapy monitoring of early-stage triple-negative breast cancer
- (2018) Mustafa Kahraman et al. Scientific Reports
- Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study
- (2018) S Adams et al. ANNALS OF ONCOLOGY
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper
- (2018) Massimo Cristofanilli et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Dysregulation of microRNAs in triple-negative breast cancer
- (2017) Sylwia Paszek et al. Ginekologia Polska
- Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study
- (2017) Lucia Nogova et al. JOURNAL OF CLINICAL ONCOLOGY
- Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2017) Sung-Bae Kim et al. LANCET ONCOLOGY
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- (2017) Mark Robson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Androgen Receptor Function and Androgen Receptor–Targeted Therapies in Breast Cancer
- (2017) Miho Kono et al. JAMA Oncology
- The genomic landscape of breast cancer and its interaction with host immunity
- (2016) Stephen Luen et al. BREAST
- Fibroblast growth factor receptor-1 protein expression is associated with prognosis in estrogen receptor-positive/human epidermal growth factor receptor-2-negative primary breast cancer
- (2016) Mai Tomiguchi et al. CANCER SCIENCE
- Panitumumab, Gemcitabine, and Carboplatin as Treatment for Women With Metastatic Triple-Negative Breast Cancer: A Sarah Cannon Research Institute Phase II Trial
- (2016) Denise A. Yardley et al. Clinical Breast Cancer
- The role of oxidative stress on breast cancer development and therapy
- (2016) Fabio Hecht et al. TUMOR BIOLOGY
- Prognostic value of androgen receptor in triple negative breast cancer: A meta-analysis
- (2016) Changjun Wang et al. Oncotarget
- Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence
- (2016) Elizabeth A. Mittendorf et al. Oncotarget
- A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors
- (2015) A. W. Tolcher et al. ANNALS OF ONCOLOGY
- Clinical implications of molecular heterogeneity in triple negative breast cancer
- (2015) Brian D. Lehmann et al. BREAST
- Expression of FGFR1 is an independent prognostic factor in triple-negative breast cancer
- (2015) Chee Leong Cheng et al. BREAST CANCER RESEARCH AND TREATMENT
- Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
- (2015) Michael S. Rooney et al. CELL
- Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer
- (2015) Holm Eggemann et al. ENDOCRINE-RELATED CANCER
- Identification of dysregulated microRNAs in triple-negative breast cancer (Review)
- (2015) FANG YANG et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Prognostic and predictive value of PDL1 expression in breast cancer
- (2015) Renaud Sabatier et al. Oncotarget
- Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors
- (2014) J.- C. Soria et al. ANNALS OF ONCOLOGY
- Low Prognostic Implication of Fibroblast Growth Factor Family Activation in Triple-negative Breast Cancer Subsets
- (2014) Hee Jin Lee et al. ANNALS OF SURGICAL ONCOLOGY
- Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer
- (2014) M. D. Burstein et al. CLINICAL CANCER RESEARCH
- Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199
- (2014) Sylvia Adams et al. JOURNAL OF CLINICAL ONCOLOGY
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
- (2014) Patricia Cortazar et al. LANCET
- Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data
- (2014) François-Clément Bidard et al. LANCET ONCOLOGY
- High EGFR gene copy number predicts poor outcome in triple-negative breast cancer
- (2014) Heae Surng Park et al. MODERN PATHOLOGY
- SGN-LIV1A: A Novel Antibody-Drug Conjugate Targeting LIV-1 for the Treatment of Metastatic Breast Cancer
- (2014) D. Sussman et al. MOLECULAR CANCER THERAPEUTICS
- Trop-2 Is a Determinant of Breast Cancer Survival
- (2014) Federico Ambrogi et al. PLoS One
- Phase II Trial of Bicalutamide in Patients with Androgen Receptor-Positive, Estrogen Receptor-Negative Metastatic Breast Cancer
- (2013) A. Gucalp et al. CLINICAL CANCER RESEARCH
- Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer
- (2013) F. Andre et al. CLINICAL CANCER RESEARCH
- Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
- (2013) Sarah-Jane Dawson et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Impact of Androgen Receptor Expression on Breast Cancer Survival: A Retrospective Study and Meta-Analysis
- (2013) Qing Qu et al. PLoS One
- DNA Mismatch Repair Deficiency in Breast Carcinoma
- (2012) Yong H. Wen et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer
- (2012) Martin Schuler et al. BREAST CANCER RESEARCH AND TREATMENT
- TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer
- (2012) Lisa A. Carey et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer
- (2012) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial
- (2011) Mogens Bernsdorf et al. BREAST CANCER RESEARCH AND TREATMENT
- RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
- (2011) Adam M. Brufsky et al. JOURNAL OF CLINICAL ONCOLOGY
- RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer
- (2011) Nicholas J. Robert et al. JOURNAL OF CLINICAL ONCOLOGY
- Increased expression of fibroblastic growth factor receptor 2 is correlated with poor prognosis in patients with breast cancer
- (2011) Shanshan Sun et al. JOURNAL OF SURGICAL ONCOLOGY
- Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study
- (2011) Laura C Collins et al. MODERN PATHOLOGY
- GP369, an FGFR2-IIIb-Specific Antibody, Exhibits Potent Antitumor Activity against Human Cancers Driven by Activated FGFR2 Signaling
- (2010) A. Bai et al. CANCER RESEARCH
- Glycoprotein Nonmetastatic B Is an Independent Prognostic Indicator of Recurrence and a Novel Therapeutic Target in Breast Cancer
- (2010) A. A. N. Rose et al. CLINICAL CANCER RESEARCH
- Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer
- (2009) B. K. Linderholm et al. ANNALS OF ONCOLOGY
- Expression of androgen receptors in primary breast cancer
- (2009) S. Park et al. ANNALS OF ONCOLOGY
- Epitope Landscape in Breast and Colorectal Cancer
- (2008) N. H. Segal et al. CANCER RESEARCH
- Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes
- (2008) C. Desmedt et al. CLINICAL CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now